538 related articles for article (PubMed ID: 32882310)
1. C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial.
Jaffe GJ; Westby K; Csaky KG; Monés J; Pearlman JA; Patel SS; Joondeph BC; Randolph J; Masonson H; Rezaei KA
Ophthalmology; 2021 Apr; 128(4):576-586. PubMed ID: 32882310
[TBL] [Abstract][Full Text] [Related]
2. Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial.
Patel SS; Lally DR; Hsu J; Wykoff CC; Eichenbaum D; Heier JS; Jaffe GJ; Westby K; Desai D; Zhu L; Khanani AM
Eye (Lond); 2023 Dec; 37(17):3551-3557. PubMed ID: 36964259
[TBL] [Abstract][Full Text] [Related]
3. Complement inhibitors for age-related macular degeneration.
Tzoumas N; Riding G; Williams MA; Steel DH
Cochrane Database Syst Rev; 2023 Jun; 6(6):CD009300. PubMed ID: 37314061
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial.
Khanani AM; Patel SS; Staurenghi G; Tadayoni R; Danzig CJ; Eichenbaum DA; Hsu J; Wykoff CC; Heier JS; Lally DR; Monés J; Nielsen JS; Sheth VS; Kaiser PK; Clark J; Zhu L; Patel H; Tang J; Desai D; Jaffe GJ;
Lancet; 2023 Oct; 402(10411):1449-1458. PubMed ID: 37696275
[TBL] [Abstract][Full Text] [Related]
5. Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial.
Liao DS; Grossi FV; El Mehdi D; Gerber MR; Brown DM; Heier JS; Wykoff CC; Singerman LJ; Abraham P; Grassmann F; Nuernberg P; Weber BHF; Deschatelets P; Kim RY; Chung CY; Ribeiro RM; Hamdani M; Rosenfeld PJ; Boyer DS; Slakter JS; Francois CG
Ophthalmology; 2020 Feb; 127(2):186-195. PubMed ID: 31474439
[TBL] [Abstract][Full Text] [Related]
6. Avacincaptad Pegol: First Approval.
Kang C
Drugs; 2023 Oct; 83(15):1447-1453. PubMed ID: 37814173
[TBL] [Abstract][Full Text] [Related]
7. The effect of complement C3 or C5 inhibition on geographic atrophy secondary to age-related macular degeneration: A living systematic review and meta-analysis.
Garg A; Nanji K; Tai F; Phillips M; Zeraatkar D; Garg SJ; Sadda SR; Kaiser PK; Guymer RH; Sivaprasad S; Wykoff CC; Chaudhary V
Surv Ophthalmol; 2024; 69(3):349-361. PubMed ID: 38008405
[TBL] [Abstract][Full Text] [Related]
8. Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study.
Yehoshua Z; de Amorim Garcia Filho CA; Nunes RP; Gregori G; Penha FM; Moshfeghi AA; Zhang K; Sadda S; Feuer W; Rosenfeld PJ
Ophthalmology; 2014 Mar; 121(3):693-701. PubMed ID: 24289920
[TBL] [Abstract][Full Text] [Related]
9. Characterizing New-Onset Exudation in the Randomized Phase 2 FILLY Trial of Complement Inhibitor Pegcetacoplan for Geographic Atrophy.
Wykoff CC; Rosenfeld PJ; Waheed NK; Singh RP; Ronca N; Slakter JS; Staurenghi G; Monés J; Baumal CR; Saroj N; Metlapally R; Ribeiro R
Ophthalmology; 2021 Sep; 128(9):1325-1336. PubMed ID: 33711380
[TBL] [Abstract][Full Text] [Related]
10. Emixustat Hydrochloride for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Clinical Trial.
Rosenfeld PJ; Dugel PU; Holz FG; Heier JS; Pearlman JA; Novack RL; Csaky KG; Koester JM; Gregory JK; Kubota R
Ophthalmology; 2018 Oct; 125(10):1556-1567. PubMed ID: 29716784
[TBL] [Abstract][Full Text] [Related]
11. Investigational drugs inhibiting complement for the treatment of geographic atrophy.
Ferro Desideri L; Artemiev D; Bernardi E; Paschon K; Zandi S; Zinkernagel M; Anguita R
Expert Opin Investig Drugs; 2023; 32(11):1009-1016. PubMed ID: 37902056
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration: Chroma and Spectri Phase 3 Randomized Clinical Trials.
Holz FG; Sadda SR; Busbee B; Chew EY; Mitchell P; Tufail A; Brittain C; Ferrara D; Gray S; Honigberg L; Martin J; Tong B; Ehrlich JS; Bressler NM;
JAMA Ophthalmol; 2018 Jun; 136(6):666-677. PubMed ID: 29801123
[TBL] [Abstract][Full Text] [Related]
13. Pegcetacoplan Treatment and Consensus Features of Geographic Atrophy Over 24 Months.
Fu DJ; Bagga P; Naik G; Glinton S; Faes L; Liefers B; Lima R; Wignall G; Keane PA; Ioannidou E; Ribeiro Reis AP; McKeown A; Scheibler L; Patel PJ; Moghul I; Pontikos N; Balaskas K
JAMA Ophthalmol; 2024 Jun; 142(6):548-558. PubMed ID: 38722644
[TBL] [Abstract][Full Text] [Related]
14. Re: Jaffe et al.: C5 inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration: a randomized pivotal phase 2/3 trial (Ophthalmology. 2021;128:576-586).
Keenan TDL
Ophthalmology; 2021 May; 128(5):e25-e26. PubMed ID: 33551286
[No Abstract] [Full Text] [Related]
15. Complement inhibition as a therapeutic strategy in retinal disorders.
Kassa E; Ciulla TA; Hussain RM; Dugel PU
Expert Opin Biol Ther; 2019 Apr; 19(4):335-342. PubMed ID: 30686077
[TBL] [Abstract][Full Text] [Related]
16. Two studies to learn if avacincaptad pegol works and is safe in people with geographic atrophy: a plain language summary of the GATHER1 and GATHER 2 studies.
Jaffe GJ; Khanani AM
Immunotherapy; 2024 Mar; 16(4):205-221. PubMed ID: 38270081
[TBL] [Abstract][Full Text] [Related]
17. Randomized Phase IIb Study of Brimonidine Drug Delivery System Generation 2 for Geographic Atrophy in Age-Related Macular Degeneration.
Freeman WR; Bandello F; Souied E; Guymer RH; Garg SJ; Chen FK; Rich R; Holz FG; Patel SS; Kim K; López FJ;
Ophthalmol Retina; 2023 Jul; 7(7):573-585. PubMed ID: 36906177
[TBL] [Abstract][Full Text] [Related]
18. PHASE 2 STUDY OF THE SAFETY AND EFFICACY OF BRIMONIDINE DRUG DELIVERY SYSTEM (BRIMO DDS) GENERATION 1 IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION.
Kuppermann BD; Patel SS; Boyer DS; Augustin AJ; Freeman WR; Kerr KJ; Guo Q; Schneider S; López FJ;
Retina; 2021 Jan; 41(1):144-155. PubMed ID: 32134802
[TBL] [Abstract][Full Text] [Related]
19. Natural History of Geographic Atrophy Secondary to Age-Related Macular Degeneration: Results from the Prospective Proxima A and B Clinical Trials.
Holekamp N; Wykoff CC; Schmitz-Valckenberg S; Monés J; Souied EH; Lin H; Rabena MD; Cantrell RA; Henry EC; Tang F; Swaminathan B; Martin J; Ferrara D; Staurenghi G
Ophthalmology; 2020 Jun; 127(6):769-783. PubMed ID: 32081489
[TBL] [Abstract][Full Text] [Related]
20. Impact of Baseline Characteristics on Geographic Atrophy Progression in the FILLY Trial Evaluating the Complement C3 Inhibitor Pegcetacoplan.
Steinle NC; Pearce I; Monés J; Metlapally R; Saroj N; Hamdani M; Ribeiro R; Rosenfeld PJ; Lad EM
Am J Ophthalmol; 2021 Jul; 227():116-124. PubMed ID: 33675755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
